Brief: Natco Pharma - Mylan Pharma, Novo Nordisk Settle U.S. Patent Litigation Over Generic Ozempic
07/10/2024 04:15
Oct 7 (Reuters) - Natco Pharma Ltd NATP.NS :
* NATCO PHARMA - MYLAN PHARMA, NOVO NORDISK SETTLE U.S.
PATENT
LITIGATION OVER GENERIC OZEMPIC
Source text for Eikon: ID:
Further company coverage: NATP.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees